447 related articles for article (PubMed ID: 10070911)
21. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
[TBL] [Abstract][Full Text] [Related]
22. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
23. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
24. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
25. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
26. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
27. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
[TBL] [Abstract][Full Text] [Related]
28. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
29. Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center.
Gobbi L; Scaparrotta G; Rigato M; Cattarin L; Qassim L; Carraro G; Rossi B; Calò LA
Ther Apher Dial; 2020 Dec; 24(6):642-647. PubMed ID: 32154642
[TBL] [Abstract][Full Text] [Related]
30. Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial.
Bhavi SB; Jaju PB
BMC Pregnancy Childbirth; 2017 May; 17(1):137. PubMed ID: 28482869
[TBL] [Abstract][Full Text] [Related]
31. Achieving target hematocrit in dialysis patients: new concepts in iron management.
Nissenson AR
Am J Kidney Dis; 1997 Dec; 30(6):907-11. PubMed ID: 9398140
[TBL] [Abstract][Full Text] [Related]
32. Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients.
Javier AM
Nephrol Nurs J; 2002 Apr; 29(2):183-6. PubMed ID: 11997953
[TBL] [Abstract][Full Text] [Related]
33. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
34. Iron supplementation in adolescent hemodialysis patients.
Nailescu C; Castaneda M; Del Rio M; Flynn JT
Clin Nephrol; 2004 Dec; 62(6):449-54. PubMed ID: 15630904
[TBL] [Abstract][Full Text] [Related]
35. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
36. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron.
Gotloib L; Silverberg D; Fudin R; Shostak A
J Nephrol; 2006; 19(2):161-7. PubMed ID: 16736414
[TBL] [Abstract][Full Text] [Related]
37. Considerations for optimal iron use for anemia due to chronic kidney disease.
Hudson JQ; Comstock TJ
Clin Ther; 2001 Oct; 23(10):1637-71. PubMed ID: 11726002
[TBL] [Abstract][Full Text] [Related]
38. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
Kaskel FJ
Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
[No Abstract] [Full Text] [Related]
40. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.
Reed BN; Blair EA; Thudium EM; Waters SB; Sueta CA; Jensen BC; Rodgers JE
Pharmacotherapy; 2015 Jan; 35(1):64-71. PubMed ID: 25556867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
